Ibandronic acid 6mg/6ml solution for infusion vials

The majority of clinical research continues to focus on evaluating the efficacy of teriparatide and bisphosphonates in the treatment of osteoporosis. This systematic review gathered data from extensive research assessing the efficacy, safety, and clinical outcomes of various medications. The objective was to determine the effectiveness and clinical implications of teriparatide and bisphosphonates in the treatment of postmenopausal osteoporosis. We analyzed 15 comprehensive studies, encompassing randomized controlled trials (RCTs), systematic reviews, and meta-analyses. The primary studies included large trials and several medium-sized trials that examined changes in bone mineral density (BMD), fracture risk, and adverse outcomes. Teriparatide significantly lowered vertebral fracture risk compared with risedronate in patients with severe osteoporosis and increased lumbar spine BMD to a comparable extent as alendronate, though via a distinct anabolic mechanism. Combination therapy with zoledronic acid resulted in greater BMD gains than either agent alone. Most adverse events were mild and transient, including injection-site reactions, nausea, and dizziness, with no significant difference in serious adverse event rates compared with bisphosphonates. Network meta-analyses indicate that romosozumab may achieve greater early spine BMD gains than teriparatide. Teriparatide is effective in lowering vertebral fracture risk and enhancing BMD in postmenopausal osteoporosis. Anabolic agents, including teriparatide, are recommended as first-line therapy for patients at very high risk of fractures (e.g., very low BMD with prevalent fractures or fractures occurring during glucocorticoid therapy), followed by a transition to antiresorptive therapy. Treatment selection should be guided by guideline-based risk stratification rather than applying a uniform stepwise approach.

Abstract licence: CC BY

Spinal cord injury (SCI) causes significant bone loss as a long-term complication, increasing fracture risk and healthcare costs. Bisphosphonates are widely studied for mitigating bone loss since they can prevent fractures and preserve rehabilitation potential in acute SCI patients. Zoledronic acid, in particular, stands out due to its high potency, dosing convenience, and better patient adherence. This review aims to evaluate the efficacy of bisphosphonates, particularly zoledronic acid, in mitigating bone loss in acute SCI. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines using PubMed, ScienceDirect, PubMed Central (PMC), Google Scholar, and Cochrane Central Register of Controlled Trials (CENTRAL) databases. Studies from January 1, 2016, to December 31, 2024, on bisphosphonate use within six months of SCI were included. Randomized controlled trials using zoledronic acid as the intervention and meta-analyses or systematic reviews covering all bisphosphonates were selected based on predefined inclusion and exclusion criteria. Eight studies, comprising three meta-analyses and five randomized controlled trials with 729 participants, were selected after quality assessment using Assessment of Multiple Systematic Reviews 2 (AMSTAR 2) and a revised Cochrane risk of bias tool for randomized trials (RoB 2). Seven studies demonstrated significant bone mineral density (BMD) improvements at the total hip, four at the lumbar spine, two at the trochanter, and five at the femoral neck. Two meta-analyses performed subgroup analyses of zoledronic acid, demonstrating substantial bone loss reduction, although comparisons with other bisphosphonates were lacking. Reductions in bone resorption markers, such as C-terminal telopeptide (CTX), were observed in five studies. While zoledronic acid exhibits strong anti-resorptive effects and allows for practical intravenous administration, its limited impact on bone formation markers, such as P1NP, and inconsistent BMD improvements across skeletal sites require further investigation. Future studies should assess long-term outcomes, utilize advanced imaging techniques, and directly compare zoledronic acid with other bisphosphonates.

Abstract licence: CC BY

BackgroundMalignant bone tumors are one of the most painful types of cancer, and their pain is very difficult to manage. Pain-relieving methods such as radiotherapy, Bone-Modifying Agents (BMAs), and radiopharmaceuticals have been explored in different studies and found to be effective pain control measures and also prevention of skeletal-related events (SREs). This meta-analysis analyzes the global burden of pain in malignant bone tumors with an emphasis on severity, health outcomes, and the efficacy of pain management interventions.MethodsNineteen randomized controlled trials and comparative studies were selected, which included patients with Malignant Bone Tumors. Treatments involved External Beam Radiotherapy (EBRT) in single or multi-fractions, BMAs (zoledronic acid, ibandronate, pamidronate, denosumab), and radiopharmaceuticals (Radium-223, Strontium-89, Samarium-153) either alone or in combination. Random-effects models were used to compute standardized mean differences (SMDs), with the evaluation of heterogeneity, Jadad score, and GRADE quality.ResultsInterventions across all subgroups were effective at relieving pain and protecting bones. One-time EBRT was shown to be as effective as standard multi-fraction treatments (SMD 0.04, 95% CI -0.02-0.1) for pain management. BMA-based treatments yielded contradictory results: denosumab versus zoledronic acid did not show a significant difference (SMD 0.01, 95% CI -0.02-0.05), whereas bisphosphonates alone resulted in a significant uplift (SMD 0.12, 95% CI 0.05-0.2, pConclusionsRadiotherapy, BMAs, and radiopharmaceuticals, either singly or in tandem, are well-tolerated for managing pain and preventing SREs in patients with malignant bone tumors, thereby providing patients with various ways to enhance their quality of life.

Abstract licence: CC BY